# StratifAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stratifai

- Industry: Healthcare IT
- Headquarters: Dresden, Germany
- Website: www.stratifai.com/
- Total disclosed funding: $13M
- Latest round: Seed (Feb 12, 2025)
- Investors on record: 8

## About

Based in Dresden, Germany, StratifAI GmbH dba StratifAI, specializes in artificial intelligence-driven precision oncology, focusing on innovative diagnostic solutions that enhance patient care through advanced biomarker insights.Founded in 2023, StratifAI GmbH is dedicated to developing cutting-edge diagnostic tools in oncology. The company is led by founder Firas Khader. It has successfully raised EUR 12.50 mn in its Seed funding round, with Picus Capital as the lead investor, alongside other notable investors such as ARVE Capital and Debiopharm Innovation Fund. The company has closed 2 deals to date and holds a current valuation of EUR 41.106 mn.StratifAI specializes in precision oncology through its innovative biomarker platform, Polaris™, which integrates histology, RNASeq, and patient outcomes to provide comprehensive insights into spatial biology. The flagship product, Polaris™ Breast, assesses the metastatic risk in early breast cancer by analyzing digitized histology slides, aiding the refinement of adjuvant treatment options. This diagnostic tool has been scientifically validated on a substantial cohort of over 6,000 patients, underscoring its reliability in clinical settings. Currently, the platform is available for research purposes while it undergoes regulatory approval in key markets, including the European Union and the United States, targeting oncology specialists and researchers.StratifAI generates revenue primarily through partnerships with healthcare institutions and research organizations, focusing on the clinical validation and deployment of its biomarker platform. Revenue transactions occur through research agreements or diagnostic service contracts, allowing clients to access the Polaris™ Breast diagnostic tool. The company actively seeks strategic investments to support commercialization in the multi-billion-euro cancer diagnostics market, working with leading venture capital firms and partners to expand its revenue streams as regulatory approvals are secured.StratifAI GmbH plans to enhance its product line by launching new diagnostic tools aimed at furthering precision oncology, although specific release dates have not been disclosed. The company aims to expand into additional international markets, particularly within the European Union and the United States, as regulatory approvals are finalized. Recent funding will support these initiatives, including the newly raised EUR 12.50 mn from the Seed funding round, facilitating the commercialization of their products and enhancing market penetration. 
In February 2025, StratifAI GmbH raised EUR 12.5 million in seed funding led by new investor Picus Capital, with participation from other new investors Alven, Heliad Equity Partners, Debiopharm Innovation Fund, Begemann Capital GmbH, MultiplexDX Inc., Neulogy Ventures and ARVE Capital. Individual and other unspecified investors also participated in the round.

## Funding rounds

- Seed, Feb 12, 2025, $13M — Alven, Heliad Equity Partners, Neulogy Ventures, Picus Capital, Debiopharm Innovation Fund, MultiplexDX Inc., Arve Capital, Begemann Capital GmbH

## Investors

- Alven (https://capitalatlas.ai/funds/alven) — Seed
- Heliad Equity Partners (https://capitalatlas.ai/funds/heliad-equity-partners) — Seed
- Neulogy Ventures (https://capitalatlas.ai/funds/neulogy-ventures) — Seed
- Picus Capital (https://capitalatlas.ai/funds/picus-capital) — Seed
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Seed
- MultiplexDX Inc. — Seed
- Arve Capital (https://capitalatlas.ai/funds/arve-capital) — Seed
- Begemann Capital GmbH — Seed